script.reportAU
Oncology

Cemiplimab

Brand: Libtayo

PBAC's latest decision on Cemiplimab: Recommended with restriction (2023). Considered for First-line treatment of adult patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC) without EGFR, ALK, or ROS1 aberrations, in combination with platinum doublet chemotherapy, irrespective of histology or PD-L1 expression levels.

PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
4
first 2020
PBS spend
$215M
28,838 scripts · 2024

Eligible population

Adult patients with Stage IV (metastatic) NSCLC without EGFR, ALK, or ROS1 aberrations, who have not previously received systemic therapy for advanced NSCLC, with WHO performance status 0 or 1

Therapy area
Oncology
Line of therapy
First-line
Evidence base
Meta-analysis
Primary endpoint
OS
Pivotal trial size
1,641 patients
Key trials
Study 16113, KN-189, KN-407
Comparator
pembrolizumab in combination with platinum doublet chemotherapy
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated by design
Risk sharing
Risk-sharing arrangement in place — Special Pricing Arrangement (SPA) applies

PBS expenditure

The Australian government paid $215M in PBS benefits for Cemiplimab in 2024 across 28,838 scripts, at $7,470 per script.

Submission history

Similar precedents

Open on full dashboard →